TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Technology #CSEStocks #SmallCaps #Investing

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–based healthcare distribution company...


http://dlvr.it/TQ5Zv8

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

ASTRA TT Signs Strategic MOU with India's BIS to Accelerate Green Charging Infrastructure Across the Nation #Publishing #Technology